MX2020004633A - Metodo para inactivar el virus de zika y metodos relacionados. - Google Patents

Metodo para inactivar el virus de zika y metodos relacionados.

Info

Publication number
MX2020004633A
MX2020004633A MX2020004633A MX2020004633A MX2020004633A MX 2020004633 A MX2020004633 A MX 2020004633A MX 2020004633 A MX2020004633 A MX 2020004633A MX 2020004633 A MX2020004633 A MX 2020004633A MX 2020004633 A MX2020004633 A MX 2020004633A
Authority
MX
Mexico
Prior art keywords
zika virus
related methods
inactivating
determining
present disclosure
Prior art date
Application number
MX2020004633A
Other languages
English (en)
Inventor
Masafumi Misaki
Jill A Livengood
Holli Giebler
Hansi Dean
Tatsuki Satou
Raman Rao
Jackie Marks
Mark Lyons
Asae Shintani
Jamie Gifford
Nao Ogasawara
Satoshi Adachi
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/059227 external-priority patent/WO2019090233A2/en
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2020004633A publication Critical patent/MX2020004633A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/22—Testing for sterility conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/74—Optical detectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente descripción se refiere a métodos para inactivar un virus de Zika que se puede usar en vacunas y composiciones inmunógenas. La presente descripción también se refiere a un método para determinar la completitud de la inactivación de una preparación de arbovirus y a un método para determinar el contenido de formaldehído residual en una composición farmacéutica que comprende un virus inactivado.
MX2020004633A 2017-11-30 2018-11-30 Metodo para inactivar el virus de zika y metodos relacionados. MX2020004633A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762592995P 2017-11-30 2017-11-30
PCT/US2018/059227 WO2019090233A2 (en) 2017-11-03 2018-11-05 Method for inactivating zika virus and for determining the completeness of inactivation
PCT/US2018/063381 WO2019108976A1 (en) 2017-11-30 2018-11-30 Method for inactivating zika virus and related methods

Publications (1)

Publication Number Publication Date
MX2020004633A true MX2020004633A (es) 2020-09-28

Family

ID=66664221

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004633A MX2020004633A (es) 2017-11-30 2018-11-30 Metodo para inactivar el virus de zika y metodos relacionados.
MX2020005554A MX2020005554A (es) 2017-11-30 2018-11-30 Vacunas y composiciones inmunogenas para zika y metodos para usarlas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020005554A MX2020005554A (es) 2017-11-30 2018-11-30 Vacunas y composiciones inmunogenas para zika y metodos para usarlas.

Country Status (11)

Country Link
US (3) US11975062B2 (es)
EP (2) EP3717638A4 (es)
JP (4) JP7443233B2 (es)
KR (2) KR20200090893A (es)
CN (4) CN116983399A (es)
AU (5) AU2018375173B2 (es)
BR (2) BR112020009960A2 (es)
CA (2) CA3085016A1 (es)
MX (2) MX2020004633A (es)
SG (2) SG11202003975WA (es)
WO (2) WO2019108976A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020004543A (es) 2017-11-03 2020-09-18 Takeda Vaccines Inc Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
MX2020004633A (es) 2017-11-30 2020-09-28 Takeda Vaccines Inc Metodo para inactivar el virus de zika y metodos relacionados.
KR102253190B1 (ko) * 2018-07-18 2021-05-18 (주)진매트릭스 지카 바이러스 변이주와 이를 포함한 지카 백신 조성물
WO2020226831A1 (en) * 2019-05-08 2020-11-12 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
RU2717993C1 (ru) * 2019-10-22 2020-03-27 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Способ получения антигена вируса Зика, обладающего иммуногенными и антигенными свойствами
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405939B (de) * 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
US6309650B1 (en) 1997-08-28 2001-10-30 Cheil Jedang Corporation Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
GB0326439D0 (en) * 2003-11-13 2003-12-17 Imp College Innovations Ltd Methods
EP1793852A1 (en) 2004-08-27 2007-06-13 Panacea Biotec Ltd. Inactivated poliomyelitis vaccine derived from sabin strain of polio virus
EP1724338A1 (en) 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
US8865184B2 (en) 2006-09-01 2014-10-21 Bharat Biotech International Limited Vaccine for chikungunya virus infection
EP2411049B1 (en) 2009-03-27 2020-01-15 Academia Sinica Methods and compositions for immunization against virus
CN101954076A (zh) 2009-04-27 2011-01-26 免疫制剂美国公司 自身免疫性肝炎的免疫疗法和预防
CN101876650B (zh) * 2010-07-02 2014-04-09 中国烟草总公司郑州烟草研究院 一种烟用水基胶中甲醛含量的测定方法
JP2014515367A (ja) 2011-05-26 2014-06-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 不活性化デング熱ウイルスワクチン
AU2012269907B2 (en) 2011-06-17 2017-05-18 Bharat Biotech International Limited Vaccine composition comprising an inactivated chikungunya virus strain
FI3785730T3 (fi) 2011-12-06 2024-05-06 Valneva Austria Gmbh Alumiiniyhdisteet terapiassa ja rokotteissa käyttöä varten
CN104159603A (zh) 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
CN102680595A (zh) * 2012-05-03 2012-09-19 安阳市双环助剂有限责任公司 分散剂mf中游离甲醛含量的测定方法
RU2706693C2 (ru) 2013-09-14 2019-11-20 Бхарат Байотек Интернэшнл Лимитед Вирусная вакцина и способы ее производства
CA2961568A1 (en) 2014-09-17 2016-03-24 The University Of Iowa Research Foundation Viral rna segments as immunomodulatory agents and vaccine components
JP6755243B2 (ja) 2014-10-07 2020-09-16 セラム インスティチュート オブ インディア プライベイト リミテッド エンテロウイルス不活化およびアジュバント吸着のための改良された方法、ならびに、それから得られる投与量減量ワクチン組成物
AR102547A1 (es) * 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
US10086061B2 (en) 2015-03-11 2018-10-02 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
EP3310382A4 (en) 2015-06-22 2019-01-02 President and Fellows of Harvard College Compositions and methods for modulating viral infection
KR20220144415A (ko) * 2015-07-16 2022-10-26 브하라트 바이오테크 인터내셔날 리미티드 백신 조성물
ES2937963T3 (es) 2015-07-21 2023-04-03 Modernatx Inc Vacunas de enfermedad infecciosa
EP3355899A4 (en) 2015-09-30 2019-04-03 Ramot at Tel-Aviv University Ltd. In place of EVOLUTIONARY PRESERVED RNA STRUCTURE MUTATED APPROVED VIRUS
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
WO2017109223A1 (en) 2015-12-23 2017-06-29 Valneva Se Virus purification
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
US11434259B2 (en) 2016-01-25 2022-09-06 Iogenetics, Llc Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity
MX2018009917A (es) 2016-02-17 2019-08-14 Curevac Ag Vacuna contra el virus del zika.
US11648303B2 (en) 2016-02-25 2023-05-16 The Trustees Of The University Of Pennsylvania Vaccines against zika virus
US20170354729A1 (en) 2016-03-16 2017-12-14 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
CN105749268B (zh) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
US20170298119A1 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
WO2017192856A1 (en) * 2016-05-04 2017-11-09 University Of Miami Zika virus vector for treating zika virus infection
EP3454895B1 (en) 2016-05-10 2024-03-27 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
US10967057B2 (en) 2016-06-02 2021-04-06 Glaxosmithkline Biologicals S.A. Zika viral antigen constructs
BR112018075440A2 (pt) 2016-06-09 2019-04-02 Beth Israel Deaconess Medical Center composições e métodos para prevenir e tratar a infecção por zika vírus
GB201610162D0 (en) 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
BR112018075513A2 (pt) 2016-06-13 2019-10-01 Us Health ácidos nucleicos que codificam as partículas seme-lhantes ao vírus da zika e seu uso nas vacinas e no ensaio de diagnóstico do vírus da zika
US10632185B2 (en) 2016-07-08 2020-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric west nile/zika viruses and methods of use
US10590174B2 (en) 2016-07-08 2020-03-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Genomic sequences encoding for an attenuated mutant Zika virus
US11834494B2 (en) 2016-07-26 2023-12-05 Washington University Antibodies to zika virus and methods of use thereof
GB201613191D0 (en) 2016-07-29 2016-09-14 Univ Oxford Innovation Ltd Zika virus vaccine
EP4043031A3 (en) 2016-11-17 2022-11-23 GlaxoSmithKline Biologicals SA Zika viral antigen constructs
EP3558353A2 (en) 2016-12-23 2019-10-30 Expres2ion Biotechnologies ApS New flavivirus vaccine
CN108503696B (zh) 2017-02-27 2023-05-12 中国科学院上海巴斯德研究所 一种酵母细胞表达的寨卡病毒亚单位疫苗
CN108503697B (zh) 2017-02-27 2023-03-31 中国科学院上海巴斯德研究所 一种果蝇细胞表达的寨卡病毒亚单位疫苗
WO2018165373A1 (en) 2017-03-08 2018-09-13 University Of Georgia Research Foundation, Inc. Methods and compositions related to increased viral production
US11370830B2 (en) 2017-04-07 2022-06-28 The Rockefeller University Neutralizing antibodies that bind to the zika virus domain III envelope region
US11286502B2 (en) 2017-06-20 2022-03-29 Texas Tech University System ZIKA virus like particle (VLP) based vaccine and microneutralization assay
EP3417943B1 (de) 2017-06-21 2020-02-12 Eppendorf AG Zentrifugenrotor mit abdichtung
CN107188935B (zh) 2017-07-20 2018-10-02 北京健乃喜生物技术有限公司 一种寨卡病毒ns1抗原突变体及其应用
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN107537029B (zh) 2017-09-14 2021-03-19 北京科兴生物制品有限公司 一种寨卡病毒与黄热病毒联合灭活疫苗
GB201716254D0 (en) 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
MX2020004543A (es) * 2017-11-03 2020-09-18 Takeda Vaccines Inc Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
WO2019104157A1 (en) 2017-11-21 2019-05-31 The University Of Vermont And State Agricultural College Highly specific zika neutralizing human antibodies
MX2020004633A (es) 2017-11-30 2020-09-28 Takeda Vaccines Inc Metodo para inactivar el virus de zika y metodos relacionados.
CN108187036A (zh) 2017-12-08 2018-06-22 北京科兴中维生物技术有限公司 一种寨卡病毒与乙脑病毒联合灭活疫苗
CN108210921A (zh) 2017-12-29 2018-06-29 广州恩宝生物医药科技有限公司 一种寨卡病毒疫苗及其制备方法
EP3755818A1 (en) 2018-02-22 2020-12-30 Nano4 Global, Lda Method for detecting flaviviridae
WO2019172982A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses
EP3773705A1 (en) 2018-03-29 2021-02-17 Emergex Vaccines Holdings Limited Vaccine compositions
KR102075581B1 (ko) 2018-04-27 2020-02-10 가톨릭대학교 산학협력단 바이러스성 발현 조절 서열이 삽입된 핵산 분자를 포함하는 면역보강제 및 이를 포함하는 약학 조성물
KR102253190B1 (ko) 2018-07-18 2021-05-18 (주)진매트릭스 지카 바이러스 변이주와 이를 포함한 지카 백신 조성물
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
WO2020087038A1 (en) 2018-10-26 2020-04-30 New York Blood Center, Inc. Zika virus immunogenic compositions
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
WO2020226831A1 (en) 2019-05-08 2020-11-12 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
US20230272405A1 (en) 2020-06-22 2023-08-31 University Of Connecticut Flavivirus signal peptides, vaccine constructs, and methods therefor

Also Published As

Publication number Publication date
CN116983399A (zh) 2023-11-03
EP3717638A1 (en) 2020-10-07
BR112020010466A2 (pt) 2020-11-24
WO2019108970A1 (en) 2019-06-06
CN116983398A (zh) 2023-11-03
AU2022235577A1 (en) 2022-10-13
EP3717638A4 (en) 2022-03-09
JP7443233B2 (ja) 2024-03-05
AU2018375789A1 (en) 2020-05-28
AU2022275515A1 (en) 2023-01-19
BR112020009960A2 (pt) 2020-11-10
CN111527104A (zh) 2020-08-11
AU2018375173B2 (en) 2022-08-25
AU2018375789B2 (en) 2021-11-11
AU2022200351B2 (en) 2022-06-23
CA3084605A1 (en) 2019-06-06
AU2018375173A1 (en) 2020-05-28
WO2019108976A1 (en) 2019-06-06
EP3717511A4 (en) 2021-09-15
CN111601885A (zh) 2020-08-28
KR20200090893A (ko) 2020-07-29
AU2022200351A1 (en) 2022-02-17
SG11202004863QA (en) 2020-06-29
JP2021505134A (ja) 2021-02-18
EP3717511A1 (en) 2020-10-07
KR20200094191A (ko) 2020-08-06
CA3085016A1 (en) 2019-06-06
US11975062B2 (en) 2024-05-07
MX2020005554A (es) 2020-10-12
US20230398199A9 (en) 2023-12-14
JP2024001177A (ja) 2024-01-09
JP2023134630A (ja) 2023-09-27
US20210403879A1 (en) 2021-12-30
US20210106669A1 (en) 2021-04-15
JP2021505549A (ja) 2021-02-18
US20240024454A1 (en) 2024-01-25
SG11202003975WA (en) 2020-06-29

Similar Documents

Publication Publication Date Title
MX2020004633A (es) Metodo para inactivar el virus de zika y metodos relacionados.
MX2020004542A (es) Metodo para inactivar el virus del zika y para determinar la inactivacion total.
UY37252A (es) Compuestos para el tratamiento de infección por virus de la hepatitis b
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
MX2018007627A (es) Vacuna contra el virus del zika.
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
EA201800108A1 (ru) Вакцинные композиции для профилактики абровирусных инфекций
ECSP18001613A (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
BR112018071048A2 (pt) combinações e métodos que compreendem um inibidor da montagem de capsídeos
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
PE20151588A1 (es) Vacuna contra el virus del dengue
CL2018000609A1 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue.
BR112017002440A2 (pt) vírus da diarreia epizoótica porcina mutante para utilização em uma vacina
CO2018002207A2 (es) Composiciones contra alergia a los gatos
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
PH12015502115A1 (en) Compositions and methods for live, attenuated alphavirus formulations
AR104271A1 (es) Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante
BR112018005291A2 (pt) composição para vacina combinada para dosagem múltipla
CL2009000287A1 (es) Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav.
AR106501A1 (es) Adyuvante y composición de vacuna que lo contiene
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
AR113831A1 (es) Métodos para desactivar un virus de zika y para determinar la desactivación total
MX2018011226A (es) Tc24-c4, antígeno de vacuna de la enfermedad de chagas con estabilidad mejorada y agregación disminuida.